Researchers led by Ball, Beck, and Wlochowitz published a large‑scale diagnostic study in the British Journal of Cancer showing that whole‑transcriptome sequencing performs robustly across 1,233 FFPE solid tumor samples. The paper details assay sensitivity, handling of degraded RNA typical of FFPE blocks, and the clinical-grade bioinformatic pipeline used to call actionable expression signatures. For molecular pathology labs and precision‑medicine programs, the work supports broader adoption of transcriptome‑level diagnostics for tumor classification and therapy selection. Regulatory and reimbursement pathways will likely hinge on prospective clinical utility studies and harmonized reporting standards.